You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

1

How does tigecycline s patent extension influence drug market competition?

See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various bacterial infections, including pneumonia, skin infections, and intra-abdominal infections [1]. The drug's patent expiration and subsequent generic entry into the market can significantly impact the drug market competition landscape. However, in the case of tigecycline, a patent extension has influenced the market competition.

Tigecycline's original patent expired in 2018 [1]. However, Wyeth, the company that originally held the patent, had filed a patent extension request under the Hatch-Waxman Act, which allows for a patent term restoration for up to five years to compensate for the time lost during the Food and Drug Administration (FDA) approval process [2]. As a result, the FDA granted Wyeth a patent extension for tigecycline, delaying the entry of generic competitors [1].

The patent extension for tigecycline has influenced the drug market competition in several ways:

1. Delayed generic entry: The patent extension has prevented generic manufacturers from entering the market and producing generic versions of tigecycline [1]. This exclusivity has allowed Wyeth to maintain its market share and pricing power.
2. Reduced competition: With the delayed entry of generic competitors, there is less competition in the tigecycline market [1]. This lack of competition can lead to higher prices for consumers and limited options for healthcare providers.
3. Limited cost savings: The patent extension has also delayed the potential cost savings associated with generic competition [1]. Generic drugs are typically less expensive than their brand-name counterparts, and their entry into the market can lead to significant cost savings for consumers, insurers, and healthcare systems [3].

In summary, the patent extension for tigecycline has influenced the drug market competition by delaying the entry of generic competitors, reducing competition, and limiting cost savings. This case study highlights the impact of patent extensions on drug market competition and the importance of monitoring drug patents and their expiration dates [1][2].

Sources:
[1] DrugPatentWatch.com. (n.d.). Tigecycline (Tygacil): Patent Expiration, Generic Entry, and Competitor Tracking. Retrieved from https://www.drugpatentwatch.com/tigecycline-tygacil-patent-expiration-generic-entry-and-competitor-tracking/
[2] U.S. Food and Drug Administration. (n.d.). The Hatch-Waxman Amendments. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/hatch-waxman-amendments
[3] Harvard Health Publishing. (2021, September 21). The high cost of prescription drugs in the U.S. Retrieved from https://www.health.harvard.edu/diseases-and-conditions/the-high-cost-of-prescription-drugs-in-the-u-s


Other Questions About Tigecycline :  Why might generic tigecycline have fewer side effects? How does increased tigecycline dosage affect liver enzymes? Can tigecycline be used to treat methicillin resistant staphylococcus aureus mrsa infections?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy